• This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Sun - Fri 8:00 - 20:30
CNBX launches new research for Melanoma Drug Candidate

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Melanoma antitumor targeting medicine. The announcement comes amidst the recent completion of a series of preclinical experiments within the company's in-house research facilities demonstrating promising antitumor results on Melanoma cell lines.

The launching of the new research program for the development of Melanoma treatment follows a previous development by the company of Cannabics® RCC-33, a proprietary formula for the treatment of Colorectal Cancer, who demonstrated a 33% reduction in tumor volume and a 35% increase in survival rate in recent in-vivo experiments in mice.

Gabriel Yariv, Cannabics Pharmaceuticals President & COO said: "The company has unique expertise and experience allowing it to develop new antitumor formulas from our built-to-spec in-house drug discovery platform. Accordingly, following our decision to develop an additional antitumor drug candidate to target Melanoma, we were able to produce high quality preclinical data, as well as identify several promising findings that we now plan to further investigate. This method of evaluation organically points towards the path of developing a new drug candidate for the treatment of Melanoma."

Eyal Barad Cannabics Pharmaceuticals' Co-founder and CEO commented: "The company plans to use this new data to initiate in-vivo animal model studies to be included in a future product package that we intend to submit to the US Food and Drug Administration along with a Pre-IND Meeting request."

Melanoma is the most serious type of skin cancer, particularly given its characteristic of spreading deeper into the skin and into other organs. According to the Skin Cancer Foundation the estimated five-year survival rate for U.S. patients whose melanoma is detected early is about 99%, and it is estimated that some 200,000 new cases of Melanoma will be diagnosed in the US in 2021 alone.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the launching of a new research program for the development of a Melanoma antitumor targeting medicine. The announcement comes amidst the recent completion of a series of preclinical experiments within the company's in-house research facilities demonstrating promising antitumor results on Melanoma cell lines.

The launching of the new research program for the development of Melanoma treatment follows a previous development by the company of Cannabics® RCC-33, a proprietary formula for the treatment of Colorectal Cancer, who demonstrated a 33% reduction in tumor volume and a 35% increase in survival rate in recent in-vivo experiments in mice.


Gabriel Yariv, Cannabics Pharmaceuticals President & COO said: "The company has unique expertise and experience allowing it to develop new antitumor formulas from our built-to-spec in-house drug discovery platform. Accordingly, following our decision to develop an additional antitumor drug candidate to target Melanoma, we were able to produce high quality preclinical data, as well as identify several promising findings that we now plan to further investigate. This method of evaluation organically points towards the path of developing a new drug candidate for the treatment of Melanoma."

Eyal Barad Cannabics Pharmaceuticals' Co-founder and CEO commented: "The company plans to use this new data to initiate in-vivo animal model studies to be included in a future product package that we intend to submit to the US Food and Drug Administration along with a Pre-IND Meeting request."

Melanoma is the most serious type of skin cancer, particularly given its characteristic of spreading deeper into the skin and into other organs. According to the Skin Cancer Foundation the estimated five-year survival rate for U.S. patients whose melanoma is detected early is about 99%, and it is estimated that some 200,000 new cases of Melanoma will be diagnosed in the US in 2021 alone.

About Cannabics Pharmaceuticals:

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.

For more information, please visit www.cannabics.com

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com.

We use cookies to ensure you get the best experience on this website Privacy Policy